Literature DB >> 22373999

Impact of 22q deletion syndrome on speech outcomes following primary surgery for submucous cleft palate.

Michael Bezuhly1, Simone Fischbach, Paula Klaiman, David M Fisher.   

Abstract

BACKGROUND: Patients with 22q deletion syndrome are at increased risk of submucous cleft palate and velopharyngeal insufficiency. The authors' aim is to evaluate speech outcomes following primary Furlow palatoplasty or pharyngeal flap for correction of velopharyngeal insufficiency in submucous cleft palate patients with and without 22q deletion syndrome.
METHODS: Records of submucous cleft palate patients who underwent primary surgery between 2001 and 2010 were reviewed. Data included 22q deletion syndrome diagnosis, age at surgery, procedure, preoperative nasopharyngoscopy and nasometry, speech outcomes, complications, and secondary surgery rates.
RESULTS: Seventy-eight submucous cleft palate patients were identified. Twenty-three patients had 22q deletion syndrome. Fewer 22q deletion syndrome patients obtained normal resonance on perceptual assessment compared with nonsyndromic patients (74 percent versus 88 percent). A similar difference existed based on postoperative nasometric scores. Among 22q deletion syndrome patients, similar success rates were achieved with Furlow palatoplasty and pharyngeal flap. No difference in the proportion improved postoperatively was noted between 22q deletion syndrome and nonsyndromic groups. One complication was experienced per group. More revision operations were indicated in the 22q deletion syndrome group (17 percent) compared with the nonsyndromic group (4 percent). Median times to normal resonance for 22q deletion syndrome and nonsyndromic patients were 150 weeks and 34 weeks, respectively. Adjusting for multiple variables, 22q deletion syndrome patients were 3.6 times less likely to develop normal resonance.
CONCLUSION: Careful selection of Furlow palatoplasty or pharyngeal flap for primary repair of submucous cleft palate is highly effective in 22q deletion syndrome patients and yields results approaching those of nonsyndromic patients. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

Entities:  

Mesh:

Year:  2012        PMID: 22373999     DOI: 10.1097/PRS.0b013e3182402e52

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  3 in total

1.  Prevalence of 22q11.2 microdeletion syndrome in Iranian patients with cleft palate.

Authors:  Narges Nouri; Mehrdad Memarzadeh; Mansoor Salehi; Nayereh Nouri; Rokhsareh Meamar; Mahdiyeh Behnam; Fatemeh Derakhshandeh; Tahereh Kashkoolinejad; Hossein Abdali
Journal:  Adv Biomed Res       Date:  2016-12-27

Review 2.  Speech-Language Disorders in 22q11.2 Deletion Syndrome: Best Practices for Diagnosis and Management.

Authors:  Cynthia B Solot; Debbie Sell; Anne Mayne; Adriane L Baylis; Christina Persson; Oksana Jackson; Donna M McDonald-McGinn
Journal:  Am J Speech Lang Pathol       Date:  2019-07-22       Impact factor: 4.018

3.  Clinical interventions and speech outcomes for individuals with submucous cleft palate.

Authors:  Seung Eun Jung; Seunghee Ha; Kyung S Koh; Tae Suk Oh
Journal:  Arch Plast Surg       Date:  2020-11-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.